ChengDa Pharmaceuticals Co. Ltd.

Chengda Pharmaceutical's 2026 interim report shows net profit attributable to the parent company of 2.2997 million yuan, down 82.07% from the same period last year. Total operating revenue was 255 million yuan, and net cash inflow from operating activities was 43.2336 million yuan. The asset-liability ratio was 10.69%, gross margin was 30.89%, return on equity was 0.11%, and diluted earnings per share was 0.02 yuan. The number of shareholders was 16,100, and the top ten shareholders held 52.04% of total share capital.

Chengda Pharmaceutical, following a self-inspection required by tax authorities, has paid back corporate income tax, property tax, value-added tax, surcharges, and late fees totaling 1.6377 million yuan. The payment has been completed and does not involve administrative penalties. The company stated that this back payment will be recorded in the current profit and loss for 2026, with the specific impact subject to the audited financial statements. Previously, Chengda Pharmaceutical had suffered losses for two consecutive years, with net losses of 28.1037 million yuan in 2024 and 11.9258 million yuan in 2025. In the first quarter of 2026, it achieved a net profit attributable to the parent company of 7.002 million yuan, a year-on-year increase of 600.15 percent.